Gyermekkori daganatok: vizsgálatok itt: Németország
143 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleA phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
- Where
- Erlangen, Essen, Muenster, Tuebingen
- People
- 48
- Run by
- Universitaet Muenster
See details and how to join2022-501725-21-00 - 4. fázisTaking peopleDabrafenib and/or Trametinib Rollover Study
- Where
- Augsburg, Essen, Hamburg, Heidelberg, Mannheim
- Életkor
- 18 év to 100 év
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - 2. fázisTaking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Berlin, Düsseldorf, Freiburg im Breisgau, München, Würzburg
- Életkor
- 12 év and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - 3. fázisTaking peopleStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
- Where
- Berlin, Bonn, Essen, Hamburg, Leipzig
- Életkor
- 15 év and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00 - 2. fázisTaking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Erlangen, Frankfurt am Main, Hamburg
- Életkor
- 1 év to 18 év
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - 4. fázisTaking peopleAsciminib Roll-over Study
- Where
- Aachen, Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mannheim, Marburg, Muenchen, Munich, Regensburg, Ulm, Wuerzburg
- Életkor
- 7 év to 100 év
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - 1. fázisTaking peopleA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Berlin, Munich, Ulm
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 - 1/2. fázisTaking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Cologne, Frankfurt Am Main, Grosshansdorf, Heidelberg
- Életkor
- 12 év and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - 1. fázisTaking peopleA Phase I Dose Finding Study of MB-CART2219.1
- Where
- Tuebingen
- Életkor
- 12 év to 75 év
- People
- 36
- Run by
- University Hospital Tuebingen
See details and how to joinNCT07108868 · EU 2024-516838-35-00 - 1/2. fázisTaking peopleA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Münster
- Életkor
- 6 hónap to 30 év
- People
- 65 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05533775 - 3. fázisTaking peopleA Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Where
- Muenster
- Életkor
- 1 év to 64 év
- People
- 130 worldwide
- Run by
- Memorial Sloan Kettering Cancer Center
See details and how to joinNCT07223021 · EU 2025-523096-34-00 - 1/2. fázisTaking peopleA Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Muenster
- Életkor
- Up to 17 év
- People
- 37 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 - No phaseTaking peopleIMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
- Where
- Aschaffenburg, Bergisch Gladbach, Erlangen, Esslingen am Neckar, Itzehoe, Kulmbach, Lübeck, Wilhelmshaven
- People
- 257
- Run by
- Institut fuer Frauengesundheit
See details and how to joinNCT07521202 - 1. fázisNot yet taking people in NémetországGD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
- Where
- Münster
- Életkor
- 1 év to 25 év
- People
- 30
- Run by
- Universität Münster
See details and how to joinNCT07897968 - 2/3. fázisTaking peopleLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Berlin, Chemnitz, Cologne, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Hamburg, Hanover, Heidelberg, Karlsruhe, Magdeburg, Munich, Regensburg, Tuebingen, Ulm, Wuerzburg
- People
- 1541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00 - No phaseNot yet taking people in NémetországAssessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
- Where
- Berlin, München
- People
- 50 worldwide
- Run by
- Aristotle University Of Thessaloniki
See details and how to joinNCT07888322 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Berlin, Cologne, Giessen, Muenster, Tuebingen
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 1/2. fázisTaking peopleA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Where
- Berlin, Cologne, Muenster
- Életkor
- 1 hónap to 17 év
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00 - No phaseTaking peopleMore Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
- Where
- Erlangen
- Életkor
- 3 év and over
- People
- 180
- Run by
- University of Erlangen-Nürnberg Medical School
See details and how to joinNCT07705178 - No phaseTaking peopleMet Non Small Cell Cancer Registry (MOMENT)
- Where
- Chemnitz, Großhansdorf, Heidelberg, Löwenstein
- People
- 700 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT05376891 - No phaseTaking peopleMaster Framework For Relapse or Refractory Acute Myeloid Leukemia
- Where
- Aachen, Greifswald, Halle, Rostock
- Életkor
- 6 év and over
- People
- 4000 worldwide
- Run by
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024 - 3. fázisTaking peopleInternational Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
- Where
- Berlin
- Életkor
- 1 év to 64 év
- People
- 750 worldwide
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00 - 2. fázisTaking peopleACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Where
- Heidelberg
- Életkor
- 12 hónap to 39 év
- People
- 60 worldwide
- Run by
- Nationwide Children's Hospital
See details and how to joinNCT06838676 - 1/2. fázisTaking peopleStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Where
- Dresden, Frankfurt Am Main, Halle (Saale), Heidelberg, Munich, Ulm
- Életkor
- 16 év and over
- People
- 85 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00 - 3. fázisTaking peopleInternational study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
- Where
- Aachen, Augsburg, Berlin, Bielefeld, Bonn, Bremen, Brunswick, Cologne, Cottbus, Datteln, Dortmund, Dresden, Düsseldorf, Erfurt, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Göttingen, Halle (Saale), Hamburg, Hanover, Heidelberg, Herdecke, Homburg, Jena, Karlsruhe, Kassel, Kiel, Koblenz, Krefeld, Leipzig, Lübeck, Magdeburg, Mainz, Mannheim, Minden, Munich, Münster, Nürnberg, Oldenburg, Ratisbon, Rostock, Stuttgart, Tuebingen, Ulm, Wuerzburg
- Életkor
- Up to 17 év
- People
- 137 worldwide
- Run by
- GPOH gGmbH
See details and how to join2022-501454-11-00